Monitor for IND submission confirmation and FDA feedback in the coming months; absence of financial details or trial start date limits near-term trading catalysts.
Price Chart
Executive Summary
Quantum Biopharma Ltd. announced the appointment of Dr. Salvatore Napoli as Principal Investigator for its planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS), a first-in-class neuroprotective compound targeting demyelination in Multiple Sclerosis. The company intends to submit an IND application to the FDA in the coming weeks, marking a key milestone in clinical development.
Key Facts
- Appointed Dr. Salvatore Napoli, MD, a recognized MS expert and Harvard-trained neurologist, as Principal Investigator for the planned Phase 2 trial of Lucid-MS.
- Lucid-MS is a patented New Chemical Entity shown in preclinical models to prevent and reverse myelin degradation in MS.
- Company plans to submit an Investigational New Drug (IND) application to the FDA in the coming weeks.
- No financial terms, trial timelines, or funding details were disclosed.
- Forward-looking statements emphasize uncertainty around future clinical development and regulatory clearance.
Financial Impact
No immediate financial impact disclosed; no revenue or cost figures provided.
Risk Factors
- Clinical trial may not proceed as planned due to regulatory delays or lack of funding.
- Preclinical results may not translate to human efficacy.
- Company has no current revenue from Lucid-MS and remains in early-stage development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001926 |
| Document: f6k_032626.htm | 0001171843-26-001926 |
| Document: 0001171843-26-001926-index-headers.html | 0001171843-26-001926 |
| Document: 0001171843-26-001926-index.html | 0001171843-26-001926 |
| Document: 0001171843-26-001926.txt | 0001171843-26-001926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 8w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 8w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers